CN1297259C - Total diterpene phenol originated from rosemary, its preparation method and use - Google Patents
Total diterpene phenol originated from rosemary, its preparation method and use Download PDFInfo
- Publication number
- CN1297259C CN1297259C CNB200410042715XA CN200410042715A CN1297259C CN 1297259 C CN1297259 C CN 1297259C CN B200410042715X A CNB200410042715X A CN B200410042715XA CN 200410042715 A CN200410042715 A CN 200410042715A CN 1297259 C CN1297259 C CN 1297259C
- Authority
- CN
- China
- Prior art keywords
- herba rosmarini
- rosmarini officinalis
- rosemary
- phenol
- total diterpene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930004069 diterpene Natural products 0.000 title claims abstract description 54
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 150000004141 diterpene derivatives Chemical class 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 title claims description 14
- 241001529742 Rosmarinus Species 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000005520 cutting process Methods 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract description 4
- 201000002313 intestinal cancer Diseases 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 210000000038 chest Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 238000004061 bleaching Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 abstract description 30
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 abstract description 10
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 abstract description 10
- 235000004654 carnosol Nutrition 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 2
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
- 230000008859 change Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 19
- 230000002107 myocardial effect Effects 0.000 description 11
- -1 diterpene phenols Chemical class 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000009465 diaoxinxuekang Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960004166 diltiazem Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to an effective part of rosemary, a preparing metod and a use thereof. The effective part of rosemary is total phenolic diterpenes extracted from a medicinal material of rosemary, and contains more than 45% of total phenol substance, wherein the main components (carnosol and carnosic acid) account for more than 13% of the total phenol substance. The preparing method comprises the following steps: after drying the rosemary medicinal material in the sun, cutting the dried rosemary medicinal material into segments; adding an extracting solution for extracting the rosemary; after cooling the combined extracting solution, filtering the extracting solution; decolorizing the filtered solution by active carbon; after concentrating the filtered liquid, adding water, filtering the solution, filtering residues, drying and crushing the residues to obtain the total phenolic diterpenes. The effective part of rosemary can be used for preparing medicines for preventing and curing cardiovascular diseases, relieving epigastric pain and curing uterine cancer, cervical carcinoma, intestinal cancer and mammary cancer. The method of extraction of the present invention is simple and practical; the obtained raw medicinal materials have high purity and good color; besides, the effective part of rosemary has the characteristics of low cost and no pollution, and is suitable for industrialization production.
Description
Technical field
The present invention relates to a kind of effective site that derives from Chinese crude drug and its production and use, specifically relate to a kind of total diterpene phenol that derives from the Herba Rosmarini Officinalis medical material and preparation method thereof and its purposes in preparing medicines such as prevention and treatment cardiovascular, alleviation obstruction of qi in the chest and cardialgia disease and treatment uterus carcinoma, cervical cancer, intestinal cancer, breast carcinoma.
Background technology
Herba Rosmarini Officinalis (Rosmarinas officinalis L.) is the herb of Labiatae (Labiatae) Rosmarinus plant, evergreen undershrub, originate in Mediterranean Region, and widely cultivation, various countries, southern Europe such as main product Spain, Morocco, Former Yugoslavia, Bulgaria and Tunisia.In recent years, also there are a large amount of cultivations China part provinces and regions, southwest (Guizhou, Yunnan).Herba Rosmarini Officinalis mainly utilizes the position to be blade, and the blade of gathering with the florescence is good, is elongated shape, green, and fragrant odour is rich in volatile oil in the leaf of Herba Rosmarini Officinalis.
Mainly contain the diterpene phenols component in the Herba Rosmarini Officinalis medical material, also have flavonoid, triterpenes and a small amount of organic acid composition in addition.The diterpene phenols component mainly contains: carnosol, carnosic acid (Wenkekt et al J.Org.chem., 1965,30 (9): 2931), Herba Rosmarini Officinalis phenol (Reiko I.et al Agric.Biol.Chem., 1982,46 (6): 1661-1666), table Herba Rosmarini Officinalis phenol, different Herba Rosmarini Officinalis phenol (Nobuji N.et al Agric.Biol.Chem., 1994,48 (8): 2081-2085) rosmarinic acid etc., with carnosol and carnosic acid is that the Herba Rosmarini Officinalis total diterpene phenolic compound of main component has good interior antioxidation action, it can suppress xanthine/ionic generation of xanthine oxidase system superoxides, also can suppress the peroxidating of microsome and mitochondrion lipid.
Research in the past focuses mostly on Herba Rosmarini Officinalis is being applied to antioxidant, with Herba Rosmarini Officinalis the effective site purposes that is used for preparing prevention and medicines such as treatment cardiovascular and cancer do not appear in the newspapers as yet.
Summary of the invention
One of purpose of the present invention be to provide a kind of derive from Herba Rosmarini Officinalis total diterpene phenols effective site.
Two of purpose of the present invention be to provide described Herba Rosmarini Officinalis the preparation method of total diterpene phenols.
Three of purpose of the present invention be to provide described Herba Rosmarini Officinalis the purposes of total diterpene phenols.
Herba Rosmarini Officinalis provided by the invention the total diterpene phenols, from the Herba Rosmarini Officinalis medical material, extract, the content of its total phenols is more than 45%.Wherein mainly based on carnosol and two chemical compounds of carnosic acid, the content sum of the two is more than 13%.
Herba Rosmarini Officinalis provided by the invention the total diterpene phenols obtain by following method:
1) pretreatment: the Herba Rosmarini Officinalis medical material after will gathering dries the back cutting, and the Herba Rosmarini Officinalis crude drug that obtains is standby;
2) extract: the extracting solution that adds 50～90% (v/v) of 5～12 times of crude drug amounts extracts 1～5 time; The extracting solution that merges is cooled to 20～60 ℃, remove by filter insoluble matter, obtain the filtrate of green and brown color;
3) decolouring: to step 2) add filtrate volume percentage by weight 0.05～0.5% (g/ml) active carbon in the filtrate that obtains,, remove by filter active carbon, clarified, the medicinal liquid of transparent rufous at 30～80 ℃ of decolouring 5～40min;
4) concentrate: it is 1.00～1.10 medicinal liquid that the filtrate that step 3) is obtained is concentrated into relative density, the water that adds 0.4～4 times of crude drug amount, stir, filter, water miscible impurity is dissolved in the filtrate and is removed, the filtering residue drying, pulverize the Herba Rosmarini Officinalis obtain pale yellow powder effective site---total diterpene phenols.
Described step 2) extracting solution is methanol, ethanol, acetone, preferred alcohol;
Described step 2) extracting mode is dipping, percolation or backflow; When selecting the reflux, extract, mode for use, extract 1～4 time, the effect during with 70% ethanol extraction 3 times is the best;
Described step 2) cool preferred 40 ℃ of temperature;
Preferred 0.1% (g/ml) of the addition of the active carbon of described step 3) is best, preferred 55 ℃ of bleaching temperature.
Herba Rosmarini Officinalis provided by the invention total diterpene phenol under oral administration route, can alleviate coronary heart disease, myocardial ischemia that angina pectoris caused effectively, can be used to the medicine for preparing prevention and treatment cardiovascular, alleviates obstruction of qi in the chest and cardialgia disease.
Herba Rosmarini Officinalis provided by the invention total diterpene phenol in body outer screening test, tumor cells such as breast carcinoma, colorectal cancer, melanoma, gastric cancer, leukemia are had and suppress and lethal effect, can be used to prepare the medicine of cancers such as treatment uterus carcinoma, cervical cancer, intestinal cancer, breast carcinoma.
Simple, the easy row of extracting method provided by the invention, with HPLC is detection means, content with carnosol and carnosic acid serves as to detect index, can carry out quality control to whole process flow effectively, reduced the oxidation of effective ingredient self in the effective site effectively, improved content of effective, the crude drug purity height that obtains, color and luster is good; In addition, this extracting method uses conventional extraction equipment, and is cheap, do not use deleterious organic solvent in the technology, pollution-free, helps protecting environment, is suitable for suitability for industrialized production.
Description of drawings
Fig. 1 is that the high performance liquid chromatogram of the Herba Rosmarini Officinalis total diterpene phenol of embodiment 1 preparation detects collection of illustrative plates; Wherein peak 1 is a carnosic acid, and peak 3 is a carnosol;
Fig. 2 is that the thin layer chromatography of the Herba Rosmarini Officinalis total diterpene phenol of embodiment 1 preparation detects collection of illustrative plates; Wherein, 1 is the carnosic acid reference substance, and 2 is the Herba Rosmarini Officinalis effective site of embodiment 1 preparation, and 3 is the carnosol reference substance.
The specific embodiment
The preparation of embodiment 1, Herba Rosmarini Officinalis total diterpene phenol
Herba Rosmarini Officinalis medical material after gathering is dried the back cutting, the alcohol reflux of 70% (v/v) of 10 times of crude drug amounts of adding 3 times; The extracting solution that merges is cooled to 40 ℃, remove by filter insoluble matter, obtain the filtrate of green and brown color; Decolouring: in this filtrate, add the active carbon of filtrate volume percentage by weight 0.1% (g/ml),, remove by filter active carbon, clarified, the medicinal liquid of transparent rufous at 55 ℃ of decolouring 20min; It is 1.10 medicinal liquid that this filtrate is concentrated into relative density, adds the water of 2 times of crude drug amounts, stirs, filter, water miscible impurity is dissolved in the filtrate and is removed, filter residue and drying, pulverizing, obtain Herba Rosmarini Officinalis total diterpene phenol of the present invention, it is a pale yellow powder, and the content of total phenols is 80%.Thin layer chromatography as Fig. 2 detects shown in the collection of illustrative plates, and it mainly contains carnosic acid and two chemical compounds of carnosol, detects as shown in Figure 1 through HPLC, and the content sum of the two is 40%.
The preparation of embodiment 2, Herba Rosmarini Officinalis total diterpene phenol
Herba Rosmarini Officinalis medical material after gathering is dried the back cutting, and the methanol percolation that adds 90% (v/v) of 5 times of crude drug amounts extracts 1 time; The extracting solution that merges is cooled to 60 ℃, remove by filter insoluble matter, obtain the filtrate of green and brown color; Decolouring: in this filtrate, add the active carbon of filtrate volume percentage by weight 0.05% (g/ml),, remove by filter active carbon, clarified, the medicinal liquid of transparent rufous at 30 ℃ of decolouring 40min; It is 1.00 medicinal liquid that this filtrate is concentrated into relative density, the water that adds 0.4 times of crude drug amount, stir, filter, water miscible impurity is dissolved in the filtrate and is removed, filter residue and drying, pulverizing, obtain pale yellow powder, be Herba Rosmarini Officinalis total diterpene phenol of the present invention, it is a pale yellow powder, and the content of total phenols is 45%.The content sum that HPLC detects carnosic acid and carnosol is 13%.
The preparation of embodiment 3, Herba Rosmarini Officinalis total diterpene phenol
Herba Rosmarini Officinalis medical material after gathering is dried the back cutting, and the acetone dipping that adds 50% (v/v) of 12 times of crude drug amounts extracts 5 times; The extracting solution that merges is cooled to 20 ℃, remove by filter insoluble matter, obtain the filtrate of green and brown color; Decolouring: in this filtrate, add the active carbon of filtrate volume percentage by weight 0.5% (g/ml),, remove by filter active carbon, clarified, the medicinal liquid of transparent rufous at 80 ℃ of decolouring 5min; It is 1.05 medicinal liquid that this filtrate is concentrated into relative density, the water that adds 4 times of crude drug amounts, stir, filter, water miscible impurity is dissolved in the filtrate and is removed, filter residue and drying, pulverizing, obtain pale yellow powder, be Herba Rosmarini Officinalis total diterpene phenol of the present invention, it is a pale yellow powder, and the content of total phenols is 60%.It mainly contains carnosic acid and two chemical compounds of carnosol, and the content sum that detects the two through HPLC is 40%.
The Herba Rosmarini Officinalis effective site of embodiment 4, mtt assay vitro detection embodiment 1 suppresses the propagation of different cell lines
1, agents useful for same
The DMEM culture medium: be on the basis of incomplete culture medium, to add 3% Glutamine 1ml, mycillin 10,000 units/ml and 10% serum (time spent adds); Hyclone, calf serum glutamine, penicillin, streptomycin
The ratio of cryopreserving liquid: DMSO and hyclone is 1: 9
MTT: be made into 5mg/ml with pH7.2 PBS, keep in Dark Place, matching while using.
Cell pyrolysis liquid: join with ultra-pure water, contain 20%SDS, 50%DMSO transfers pH4.5
2, used cell line: cancerous cell (KB), leukemia (HL60), cervical cancer cell (HeLa), colorectal cancer cells (HT29), breast cancer cell (MCF7 and MDA231) at the bottom of stomach cancer cell (BGC823), melanoma cell (WM451), the jaw
3, cell culture:
All with the RPMI1640 or the DMEM culture fluid of the hyclone/calf serum that contains 10% deactivation, cell culture went down to posterity once in 37 ℃, 5%CO2 incubator in 2-3 days.
4, the Herba Rosmarini Officinalis effective site (the following Herba Rosmarini Officinalis total diterpene phenol that all is called for short) of embodiment 1 preparation is to the mensuration of different tumor cell proliferation indexs:
Adopt mtt assay to analyze.Collect the conventional tumor cell of cultivating respectively, according to the 2000cells/ hole, 96 orifice plates are inoculated in 4000cells/ hole and 5000cells/ hole, every kind of cell is done 6 repeating holes, cultivation is in containing the DMEM culture medium of 10% hyclone, cultivate after the 24h, supernatant discarded, every hole adds Herba Rosmarini Officinalis total diterpene phenol more respectively, and (drug level is respectively 100 μ g/ml, 50 μ g/ml, 10 μ g/ml, 1 μ g/ml) DMEM 0.1ml, continue to be cultured to 48-72hr and begin to detect, it is the MTT of 500 μ g/ml that every hole adds concentration, cultivate after the 4-6h, the centrifugal supernatant of abandoning of 1900rpm15min adds buffer and each 0.1ml of cell pyrolysis liquid of PBS pH7.2 respectively, after 37 ℃ of overnight incubation, on BioTek Elisa Reader, read the absorption value of OD570nm.The results are shown in table 1.
Table 1, Herba Rosmarini Officinalis total diterpene phenol are to growth of tumour cell suppression ratio (%)
By the result of table 1 as can be seen, Herba Rosmarini Officinalis effective site provided by the invention suppresses all kinds of tumor cell proliferations external, for above-mentioned each cell line stomach cancer cell (BGC823), melanoma cell (WM451), cancerous cell at the bottom of the jaw (KB), leukemia (HL60), cervical cancer cell (HeLa), colorectal cancer cells (HT29), breast cancer cell (MCF7 and MDA231) is in concentration during at 100ug/ml, tumor growth all there is inhibitory action significantly, suppression ratio is all greater than 50%, wherein to breast cancer cell MCF7 concentration when the 10ug/ml, inhibition rate of tumor growth is still greater than 50%.
This experimental result has been pointed out the application of Herba Rosmarini Officinalis effective site provided by the invention in the preparation antitumor drug.
The test of Herba Rosmarini Officinalis effective site aspect cardiac vascular activity of embodiment 5, embodiment 1
1, to the anesthetized dog hemodynamic effects
Experimental technique: 36 of hybrid dogs, be divided into 6 groups, 6 every group, all adopt duodenal administration, administration is grouped as follows:
Experimental group I: Herba Rosmarini Officinalis total diterpene phenol (being the Herba Rosmarini Officinalis effective site of embodiment 1 preparation) 50mg/kg hereinafter to be referred as Herba Rosmarini Officinalis total diterpene phenol;
Experimental group II: Herba Rosmarini Officinalis total diterpene phenol 100mg/kg;
Experimental group III: Herba Rosmarini Officinalis total diterpene phenol 200mg/kg;
Positive controls: DIAOXINXUE KANG 32mg/kg;
Matched group: wait the capacity solvent;
With pentobarbital sodium 30mg/kg i.v. anesthesia hybrid dog, back of the body position is fixing, and skin of neck cuts, and tracheal intubation connects electric pulmotor, separates right carotid, connects the AP-601G amplifier, measures blood pressure.Separate femoral artery, connect the AP-601G amplifier, carry out the ventricle interpolation pipe, measure left indoor pressure, end diastolic pressure, and through maximum the rate of change (± dp/dt of differential processor EQ-601G mensuration left indoor pressure
Max).The 4th intercostal is executed thoracotomy in the left side, exposes heart, cuts off pericardium, does the pericardium art.Separate LCA and aortic root, place the electromagnetic flowmeter probe, measure coronary flow and aorta flow.Extremity connect limb lead, and bioassay standard II leads electrocardiogram, calculate heart rate.Separate duodenum, in order to administration.Above-mentioned each index synchronous recording is in polygraph.Art finishes, and stablize 15min, reach medicine before the record administration after, 30,60,120,150, all indexs of 240min.Before administration and behind the medicine 30,60,120,150,240min gets tremulous pulse, coronary sinus vein blood, measures oxygen content with blood oxygen instrument (Kang Ni-158, produced in USA).And, calculate two-level index: mean arterial pressure, cardiac index, SI, stroke work index, total peripheral resistance, coronary resistance, myocardial oxygen consumption, myocardial oxygen consumption index, myocardium oxygen uptake rate, myocardial flow etc. according to formula.Experimental data measured value and variation fraction values and matched group are relatively organized a t inspection statistics analysis.
Experimental result:
(1) to the influence of myocardial flow: list in table 2, the result shows that the variation percentage rate of reagent Herba Rosmarini Officinalis total diterpene phenol 50mg/kg dosage group myocardial flow significantly increases (P＜0.05) at 60～150min.The variation percentage rate of 100mg/kg dosage group myocardial flow significantly increases (P＜0.05) at 60～240min, the myocardial flow measured value significantly increases (P＜0.05) at 120min.200mg/kg dosage group changes percentage rate at 45～180min and significantly increases (P＜0.01), and measured value significantly increases (P＜0.05) at 90～120min.
(2) to the influence of coronary resistance: list in table 3, the result shows that Herba Rosmarini Officinalis total diterpene phenol 50mg/kg dosage group makes coronary resistance change percentage rate significantly descend at 90～150min (P＜0.05).100mg/kg dosage group changes percentage rate significantly descend at 60～150min (P＜0.05).200mg/kg dosage group changes percentage rate significantly descend (P＜0.01) at 60～240min.
Table 2, Herba Rosmarini Officinalis total diterpene phenol to the influence of dog myocardial flow (ml/100g.min) (X ± S, n=6)
| Group | Dosage mg/kg | Before the administration | After the administration | ||||
| 30 | 60 | 120 | 150 | 240 | |||
| The solvent matched group | 116.17± 29.095 | 113.38± 31.724 | 113.38± 31.724 | 107.30± 27.613 | 109.06± 32.549 | 105.43± 28.256 | |
| ％ | -2.79± 9.557 | -2.79± 9.557 | -7.49± 8.997 | -6.78± 10.143 | -9.21± 11.643 | ||
| DIAOXINXUE KANG | 32 | 124.37± 42.919 | 121.00± 37.687 | 121.00± 37.687 | 145.23± 46.980 | 139.58± 43.431 | 131.02± 48.172 |
| ％ | -1.70± 5.675 | -1.70± 5.675 | 18.32± 17.712 ΔΔ | 13.57± 13.164 Δ | 4.79± 4.947 Δ | ||
| Experimental group I | 50 | 103.27± 19.513 | 104.04± 15.614 | 104.04± 15.614 | 114.94± 11.944 | 115.54± 15.965 | 96.36± 17.093 |
| ％ | 1.55± 6.798 | 1.55± 6.798 | 13.35± 15.165 Δ | 13.88± 17.984 Δ | -6.52± 5.625 | ||
| Experimental group II | 100 | 125.17± 29.010 | 125.01± 26.906 | 125.01± 26.906 | 145.46± 21.873 * | 138.61± 25.498 | 134.67± 23.304 |
| ％ | 0.35±5.324 | 0.35±5.324 | 18.36± 12.346 ΔΔ | 12.74± 15.961 Δ | 9.99± 17.584 Δ | ||
| Experimental group III | 200 | 112.86± 22.604 | 116.11± 18.654 | 116.11± 18.654 | 144.18± 15.805 * | 136.66± 19.758 | 125.46± 18.755 |
| ％ | 3.88± 7.290 | 3.88± 7.290 | 31.92± 27.872 ΔΔ | 23.56± 18.876 ΔΔ | 13.43± 17.428 Δ | ||
Compare * P＜0.05, * * P＜0.01 with normal saline group measured value;
Change percentage comparisons with the normal saline group
ΔP＜0.05,
The Δ ΔP＜0.01 (down together)
Table 3, Herba Rosmarini Officinalis total diterpene phenol to the influence of dog coronary resistance (Kpa/ml/100/min) (X ± S, n=6)
| Group | Dosage mg/kg | Before the administration | After the administration | ||||
| 30 | 60 | 120 | 150 | 240 | |||
| The solvent matched group | 0.11± 0.031 | 0.12± 0.041 | 113.38± 31.724 | 0.12± 0.042 | 109.06± 32.549 | 105.43± 28.256 | |
| ％ | -0.51± 10.463 | -2.79± 9.557 | 3.62± 10.334 | -6.78± 10.143 | -9.21± 11.643 | ||
| DIAOXINXUE KANG | 32 | 0.12± 0.036 | 0.11± 0.032 | 121.00± 37.687 | 0.09± 0.029 | 139.58± 43.431 | 131.02± 48.172 |
| ％ | -1.22± 4.745 | -1.70± 5.675 | -18.31± 13.593 Δ | 13.57± 13.164 Δ | 4.79± 4.947 Δ | ||
| Experimental group I | 50 | 0.14± 0.031 | 0.13± 0.024 | 104.04± 15.614 | 0.11± 0.018 | 115.54± 15.965 | 96.36± 17.093 |
| ％ | -2.03± 7.648 | 1.55± 6.798 | -16.14± 10.950 ΔΔ | 13.88± 17.984 Δ | -6.52± 5.625 | ||
| Experimental group II | 100 | 0.11± 0.028 | 0.11± 0.026 | 125.01± 26.906 | 0.09± 0.015 | 138.61± 25.498 | 134.67± 23.304 |
| ％ | -4.48± 5.392 | 0.35± 5.324 | -17.59± 7.848 ΔΔ | 12.74± 15.961 Δ | 9.99± 17.584 Δ | ||
| Experimental group III | 200 | 0.12± 0.025 | 0.12± 0.026 | 116.11± 18.654 | 0.09± 0.011 | 136.66± 19.758 | 125.46± 18.755 |
| ％ | -5.45± 10.358 | 3.88± 7.290 | -27.16± 15.484 ΔΔ | 23.56± 18.876 ΔΔ | 13.43± 17.428 Δ | ||
Experiment conclusion: above experimental result shows that Herba Rosmarini Officinalis total diterpene phenol 100-200mg/kg dosage can significantly increase myocardial flow, reduce coronary resistance.These effects of Herba Rosmarini Officinalis total diterpene phenol, relevant with direct coronary artery dilating, making it myocardial flow increases, and directly reflects the raising of cardiac pumping function and increases the peripheral blood vessel expansion.
2, the influence of the rat heart muscle ischemia that pituitrin is caused
Get 60 of the healthy SD rats of body weight 220～240g, male and female half and half are divided into 6 groups at random, the blank group, and the diltiazem group (diltiazem, 50mg/kg), DIAOXINXUE KANG JIAONANG (200mg/kg), the high, medium and low dosage group of Herba Rosmarini Officinalis (600,300,150mg/kg).Successive administration 7d, last day is after 30min after the administration is with pentobarbital sodium ip anesthesia, facing upward the position is fixed on the Mus platform, limb lead, electrocardiograph choice criteria voltage 1mv=20mm, chart speed 50mm/s traces normal II and leads behind the electrocardio, annotated in the sublingual vein injection of pituitrin (1U/kg), 5s.Trace the electrocardiogram ECG II of 5s, 15s, 30s, each time point of 3min respectively.
Statistical method: the J point, the T ripple that calculate each time point change and rate of change X ± s, do t check between group.
Experimental result:
(1) rat ECG II J point is changed and the influence of rate of change: list in table 4, the result shows that Herba Rosmarini Officinalis high dose (600mg/kg) can significantly resist the variation (P＜0.01) that J is ordered at 5s and 15s, from rate of change, middle dosage (300mg/kg) relatively has significant difference (P＜0.05) in rate of change and the blank group of 5s and 15s.This result show Herba Rosmarini Officinalis can alleviate cause by myocardial ischemia raising of ordering of J or reduce, its effect is relevant with dosage.
(2) influence that rat ECG II T ripple is changed: list in table 5, the result shows from the T ripple and changes, Herba Rosmarini Officinalis total diterpene phenol high dose group (600mg/kg) and middle dosage group (300mg/kg) change the inhibition (P＜0.05 or P＜0.01) that has in various degree at the right T ripple of different time points, and low dosage can not effectively suppress the T ripple variation that pituitrin causes.This result shows that Herba Rosmarini Officinalis can alleviate the variation of T ripple, and its effect is relevant with dosage.
Table 4, Herba Rosmarini Officinalis cause the influence of rat ECG II J point height change to pituitrin
| Group | Normally | 5s | 15s | 30s | 3min | |
| Blank | 0.80± 0.42 | Change (mm) | 2.95±1.79 | 3.85±1.53 | 1.60±1.26 | 0.95±1.12 |
| Rate of change (%) | 417±346 | 498±287 | 237±219 | 122±130 | ||
| Diltiazem | 0.67± 0.45 | Change (mm) | 0.53±0.75 ** | 0.92±0.93 ** | 1.07±0.92 | 0.80±0.75 |
| Rate of change (%) | 94±147 * | 119±122 ** | 169±119 | 88±83 | ||
| DIAOXINXUE KANG 200mg/kg | 0.70± 0.63 | Change (mm) | 1.90±1.54 | 1.90±1.71 * | 1.25±0.95 | 0.95±0.69 |
| Rate of change (%) | 257±239 | 246±203 * | 161±178 | 79±70 | ||
| Herba Rosmarini Officinalis total diterpene phenol 600mg/kg | 0.60± 0.46 | Change (mm) | 0.90±1.35 ** | 1.55±1.48 ** | 1.8±1.7 | 0.7±0.42 |
| Rate of change (%) | 186±318 | 129±49 ** | 164±138 | 86±48 | ||
| Herba Rosmarini Officinalis total diterpene phenol 300mg/kg | 0.90± 0.74 | Change (mm) | 1.00±1.22 | 2.7±2.08 | 1.40±1.07 | 0.95±0.69 |
| Rate of change (%) | 114±111 * | 250±165 * | 125±109 | 100±76 | ||
| Herba Rosmarini Officinalis total diterpene phenol 150mg/kg | 0.80± 0.79 | Change (mm) | 1.25±1.27 | 2.45±1.66 | 1.55±1.30 | 1.30±0.86 |
| Rate of change (%) | 181±152 | 306±207 | 117±98 | 117±113 |
Table 5, Herba Rosmarini Officinalis cause the influence that rat ECG II T wave height changes to pituitrin
| Group | Normally | 5s | 15s | 30s | 3min | |
| Blank | 1.80± 0.35 | Change (mm) | 2.05±1.96 | 2.80±2.12 | 1.1±1.17 | 0.25±0.42 |
| Rate of change (%) | 108±99 | 162±125 | 73±93 | 13±22 | ||
| Diltiazem | 1.65± 0.34 | Change (mm) | 0.45±0.37 * | 0.55±0.37 ** | 0.75±0.35 | 0.3±0.35 |
| Rate of change (%) | 30±30 * | 33±21 ** | 48±29 | 20±22 | ||
| DIAOXINXUE KANG 200mg/kg | 1.85± 0.47 | Change (mm) | 1.05±0.90 | 0.85±1.00 * | 0.65±0.63 | 0.40±0.39 |
| Rate of change (%) | 61±53 | 54±69 * | 32±29 | 25±31 | ||
| Herba Rosmarini Officinalis total diterpene phenol 600mg/kg | 2.05± 0.50 | Change (mm) | 0.65±0.91 | 0.35±0.82 ** | 0.55±0.50 | 0.55±0.50 |
| Rate of change (%) | 32±45 | 17±40 | 27±24 | 27±24 | ||
| Herba Rosmarini Officinalis total diterpene phenol 300mg/kg | 2.00± 0.41 | Change (mm) | 0.75±0.92 | 1.05±1.36 * | 0.50±0.47 | 0.35±0.41 |
| Rate of change (%) | 40±56 | 53±68 * | 25±23 | 18±19 | ||
| Herba Rosmarini Officinalis total diterpene phenol 150mg/kg | 1.7±0. 75 | Change (mm) | 0.75±0.68 | 1.60±1.26 | 0.55±0.50 | 0.60±0.77 |
| Rate of change (%) | 50±47 | 101±73 | 32±31 | 32±34 |
Experiment conclusion: this experimental result shows, raising or reducing of rat ECG II J point that Herba Rosmarini Officinalis total diterpene phenol 300-600mg/kg causes pituitrin and T ripple has remarkable inhibitory action, show to improve and shrink, cause deficiency myocardial blood supply, thereby suppress myocardial ischemia by coronary artery.
This experimental result has pointed out Herba Rosmarini Officinalis effective site Herba Rosmarini Officinalis total diterpene phenol provided by the invention to prevent and treat cardiovascular in preparation, alleviate the application in the obstruction of qi in the chest and cardialgia disease drug.
Claims (8)
1, a kind of Herba Rosmarini Officinalis total diterpene phenol that from the Herba Rosmarini Officinalis medical material, extracts, it is for to be obtained by following method:
1) pretreatment: the Herba Rosmarini Officinalis medical material after will gathering dries the back cutting, and the Herba Rosmarini Officinalis crude drug that obtains is standby;
2) extract: the extracting solution that adds 50～90v/v% of 5～12 times of crude drug amounts extracts 1～5 time; The extracting solution that merges is cooled to 4～40 ℃, remove by filter insoluble matter, obtain the filtrate of green and brown color; Described extracting solution is methanol, ethanol or acetone;
3) decolouring: to step 2) add filtrate volume percentage by weight 0.05～0.5% active carbon in the filtrate that obtains,, remove by filter active carbon, clarified, the medicinal liquid of transparent rufous at 30～80 ℃ of decolouring 5～40min;
4) concentrate: it is 1.00～1.10 medicinal liquid that the filtrate that step 3) is obtained is concentrated into relative density, add 0.4～4 times to the water of crude drug amount, stir, filter, water miscible impurity is dissolved in the filtrate and is removed, the filtering residue drying, pulverize obtain Herba Rosmarini Officinalis effective site.
2, Herba Rosmarini Officinalis total diterpene phenol as claimed in claim 1 is characterized in that described step 2) extracting solution be ethanol.
3, Herba Rosmarini Officinalis total diterpene phenol as claimed in claim 1 is characterized in that described step 2) extracting mode for the dipping, percolation or backflow.
4, Herba Rosmarini Officinalis total diterpene phenol as claimed in claim 3 is characterized in that, described reflux, extract, method is with 70% ethanol extraction 3 times.
5, Herba Rosmarini Officinalis total diterpene phenol as claimed in claim 1 is characterized in that described step 2) the temperature that cools be 25 ℃.
6, Herba Rosmarini Officinalis total diterpene phenol as claimed in claim 1 is characterized in that, the addition of the active carbon of described step 3) is 0.1%, and bleaching temperature is 50 ℃.
7, the application of the described Herba Rosmarini Officinalis total diterpene of a kind of claim 1 phenol in the medicine for preparing prevention and treatment cardiovascular, alleviation obstruction of qi in the chest and cardialgia disease.
8, the application of the described Herba Rosmarini Officinalis total diterpene of a kind of claim 1 phenol in the medicine of preparation treatment uterus carcinoma, cervical cancer, intestinal cancer, breast carcinoma etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410042715XA CN1297259C (en) | 2004-05-21 | 2004-05-21 | Total diterpene phenol originated from rosemary, its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410042715XA CN1297259C (en) | 2004-05-21 | 2004-05-21 | Total diterpene phenol originated from rosemary, its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698587A CN1698587A (en) | 2005-11-23 |
| CN1297259C true CN1297259C (en) | 2007-01-31 |
Family
ID=35474940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410042715XA Expired - Fee Related CN1297259C (en) | 2004-05-21 | 2004-05-21 | Total diterpene phenol originated from rosemary, its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1297259C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007233684A1 (en) * | 2006-04-03 | 2007-10-11 | Nestec S.A. | Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same |
| CN102697758A (en) * | 2012-06-12 | 2012-10-03 | 昆明理工大学 | Application of cryptomeriol in preparation of anti-tumor angiogenesis medicine |
| BR102014022486B1 (en) * | 2014-09-11 | 2021-03-23 | Universidade Estadual De Campinas - Unicamp | PROCESS OF PURIFICATION OF JAMBU EXTRACT, PURIFIED EXTRACT SO OBTAINED, ANESTHETIC AND BIO ADHESIVE COMPOSITION CONTAINING PURIFIED JAMBU EXTRACT; EUSOS |
| CN104530074A (en) * | 2015-01-07 | 2015-04-22 | 浙江泰康生物科技有限公司 | Method for extracting carnosol from complete salvia |
| WO2019241584A1 (en) * | 2018-06-14 | 2019-12-19 | Mars, Incorporated | Composition for supporting animal with cancer |
| CN113244222B (en) * | 2020-02-12 | 2022-10-25 | 华东师范大学 | Application of carnosol compound in preparing medicine for treating cachexia |
| CN116270798A (en) * | 2023-02-07 | 2023-06-23 | 中国科学院植物研究所 | Use of rosemary extract in synergistic UV radiation for inhibiting proliferation and promoting apoptosis of various cancer cells |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256700A (en) * | 1990-10-06 | 1993-10-26 | Nestec S.A. | Carnosic acid obtention and uses |
| CN1113514A (en) * | 1995-01-13 | 1995-12-20 | 金坚敏 | Efficient natural antioxidants and their preparation |
| CN1327038A (en) * | 2001-07-18 | 2001-12-19 | 孙传经 | Process for extracting rosemary antioxidant by super-critical reverse CO2 extraction |
| CN1600353A (en) * | 2003-09-26 | 2005-03-30 | 上海市新文达生物科技有限公司 | Extractive of rosemary, preparation method and application |
-
2004
- 2004-05-21 CN CNB200410042715XA patent/CN1297259C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256700A (en) * | 1990-10-06 | 1993-10-26 | Nestec S.A. | Carnosic acid obtention and uses |
| CN1113514A (en) * | 1995-01-13 | 1995-12-20 | 金坚敏 | Efficient natural antioxidants and their preparation |
| CN1327038A (en) * | 2001-07-18 | 2001-12-19 | 孙传经 | Process for extracting rosemary antioxidant by super-critical reverse CO2 extraction |
| CN1600353A (en) * | 2003-09-26 | 2005-03-30 | 上海市新文达生物科技有限公司 | Extractive of rosemary, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1698587A (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1297259C (en) | Total diterpene phenol originated from rosemary, its preparation method and use | |
| CN105250366B (en) | Dracocephalum moldavica extract and preparation method and application thereof | |
| CN101485694B (en) | Method for extracting Ganoderma lucidum triterpenes components | |
| CN1257918C (en) | Lilyturf root polysaccharide MDG-1 and its separation method and application | |
| CN101229223B (en) | Applications of fructus psoraleae extractive on preparing antitumor medicines | |
| CN101028328A (en) | Production and use for kaki-leaf extract | |
| CN1895307A (en) | Chinese-medicinal extract for treating cardiovascular disease, its preparation and use | |
| CN103933541B (en) | A kind of glutathion anti-cancer composition | |
| CN1291735C (en) | Chinese medicine drippling pill preparation for promoting blood circulation and removing blood stasis, promoting Qi circulation and rilieving pain | |
| CN109806304A (en) | The preparation method of three leaf raspberry plant extracts and its pharmaceutical composition and anti-trichina purposes | |
| CN1907312A (en) | Use of centipeda volatile oil in preparation of tumor growth and proliferation inhibitor | |
| CN1282467C (en) | Medicine for treating coronary disease and stenocardia and its preparation method | |
| CN108524576B (en) | Pharmaceutical composition for treating impotence, medicine and preparation method of medicine | |
| CN1176677C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1302792C (en) | Medicine composition with the action of relieving alcoholism and protecting liver and its application | |
| CN101062895A (en) | Iso chicoric acid and extraction separation method thereof and usage in medicament | |
| CN103113196A (en) | Glechoma longituba phenol, and preparation method and application thereof | |
| CN1628649A (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN1879764A (en) | Medical use of iris | |
| CN1093416C (en) | Plant Medicine for treating cardiovascular medicine and its preparing process | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN101040905A (en) | Medicine made by selfheal for reducing blood sugar | |
| CN1259934C (en) | Haw leaf injection for treating cardiovascular disease | |
| CN1290510C (en) | Pharmaceutical composition containing gen-seng total saponin and astragalus root total saponin, its preparing process and application | |
| CN1103600C (en) | Medicinal composition of treating asthma and pulmonary hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BAIYUNSHAN CHINESE HUTCHISON WHAMPOA LT Free format text: FORMER OWNER: BEIJING HUAYI SHENNONG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20080711 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080711 Address after: No. 389 Sha ha North Road, Baiyun District, Guangzhou Patentee after: HUTCHISON WHAMPOA GUANGZHOU BAIYUNSHAN CHINESE MEDICINE Co.,Ltd. Address before: Room 4, layer 411, building 38, Xueyuan Road, Beijing Patentee before: Beijing Huayi Shennong Pharmaceutical Technology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070131 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |